News 
Market Data 
Discover
Replies to post #71954 on Cytodyn Inc (CYDY)
04/28/20 9:07 PM
04/28/20 10:09 PM
04/28/20 11:07 PM
Leronlimab-Saving Lives in Covid-19 Fight
In the race for covid-19 treatment therapies, an underdog has emerged with an experimental drug that is surprising doctors and saving lives. Leronlimab is an HIV drug in the late stages of FDA approval clinical trials owned by Washington State's small bio company CytoDyn Inc. Concurrently Leronlimab is also in two FDA covid-19 clinical trials treating coronavirus victims, sponsored by Novant Health in the U.S.and the U.K.s Department of Health. The early results from their compassionate use cases are turning heads inside the medical community as patients are being removed from ventilators.
Leronlimab is being injected into mild,moderate and severe patients in an attempt to curb or eliminate the
" cytokine storm ", the immune systems response that destroys the lungs in severe patients and in many cases leads to death. According to CytoDyn's Chief Executive Officer Bruce Patterson M.D , " Critically ill patients are experiencing the benefit of extubating within 7 days of treatment with leronlimab ". One patient was actually taken off of a heart/lung bypass machine after receiving the treatment.
Mild to moderate patients have also seen dramatic improvement , in most cases being taken off oxygen and released from hospital next day. No other treatment in the world today has been as successful. in spite of these remarkable results, lenorlimab is flying under the radar in the larger covid-19 public arena. It is being overshadowed by big pharma companies such as Gilead, which has launched a massive media campaign while it sits at the table with president Trump benefiting from the political backing of Washington.
None the less, CytoDyn pushes on with the recommendations of all who have witnessed lenorlimabs's stunning results ,while demand for this treatment is growing larger across the country.
According to CEO Nader Pourhassan , on April 9 ,CytoDyn's results were presented to the FDA in an attempt to secure emergency use approval (EUA) for the immediate use of lenorlimab as a primary front line therapy.
The FDA is very familiar with the drug lenorlimab , positively reviewing its safety and efficacy profile in over 800 patients in several previous CytoDyn clinical trials for other indications , most notably HIV and breast cancer.
In my view, given the results of the FDA's own protocols as managed by CytoDyn and performed by several heroic doctors, it would defy logic and amount to administrative malpractice for the FDA to do anything short of give its blessings tor lenorlimab.
Should political preferential bias play any part in the delaying or holding back of widespread use for this application the consequences would be dire indeed, not only for the credibility of the FDA itself but more importantly for the survival of countless lives at this critical juncture. As the world desperately seeks a therapy..all eyes are now on the FDA to show its leadership and unleash the potential of leronlimab..... anything less would be tragic. Can this underdog free itself from the grinding gears of big pharma's boiler room lobby machine and the politicians who operate it ? Time will tell...but don't conspire to long.......... people are dying.
AI
